Not for release or distribution or publication in whole or part in or into the United States, Canada, Japan or Australia
|
11/23/2005 Press Release
BioAlliance Pharma SA announces AMF approval of its prospectus in connection with its planned IPO on Euronext
Indicative price range between EUR12.40 and EUR14.20
Paris, 23 November 2005— BioAlliance Pharma SA, a biopharmaceutical company focused on the development and commercialisation of innovative therapeutics in the field of drug resistance, announced today that it has obtained approval from the French Autorité des Marchés Financiers (AMF) for its prospectus (AMF Visa number 05-803 dated November 22, 2005) relating to its intended Initial Public Offering on Euronext Eurolist Compartment C.
BioAlliance Pharma SA is seeking to raise gross proceeds of approximately EUR30 million through a placing of new ordinary shares to institutional investors in France and other European jurisdictions, as well as to the public in France. The public offering in France is expected to total up to 10 per cent of the total amount raised.
The indicative price range has been set at EUR12.40 to EUR14.20 per share. The offering is expected to be completed by early December. The company intends to use the net proceeds from the offering for (i) the commercial launch of its lead product, miconazole Lauriad®, currently in registration in Europe with approval expected in late 2006; (ii) the funding and advancement of products in its clinical and preclinical pipeline; and, (iii) general corporate purposes, including the maintenance and development of the company’s patent portfolio.
“These funds will enable BioAlliance to launch its lead product in Europe and to commercialise other products through further development and partnering arrangements,” commented Dominique Costantini, MD, president and CEO of BioAlliance Pharma. “This effort is part of our strategic focus on developing therapeutics to address areas representing clear unmet medical needs and attractive market opportunities.”
Before taking an investment decision, investors are invited to examine carefully the risks described in the company’s prospectus approved by the AMF (visa number 05-803) (in section 3 of the company’s “Document de base” filed with the AMF under the number I.05-132 and dated 15 November 2005 and in section 2 of the “Note d’opération” dated 22 November 2005).
All these risks or one of these risks, or risks not yet identified or considered as negligible, could have a negative effect on the activities, the financial situation, the results and the development of BioAlliance Pharma, or on the price of shares.
Advisers
Bryan Garnier & Co. Ltd, 33, avenue de Wagram – 75017 Paris
ING Securities Bank (France), Coeur Défense - Tour A - La Défense 4, 110, Esplanade du Général de Gaulle, 92931 Paris, France
Copies of the prospectus may be obtained from the AMF website http://www.amf-france.org or from the company’s website http://www.bioalliancepharma.com or by post from the company.
About BioAlliance Pharma
BioAlliance Pharma is a privately-held biopharmaceutical company specialised in the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections. The company is developing three broad product ranges based on the Lauriad® adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities programme focused on development of new drugs in oncology and HIV.
The company’s most advanced product, the miconazole Lauriad® 50 mg Bioadhesive Buccal Tablet, has just completed Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In September 2005, this product was the subject of a request for Marketing Authorisation for Europe and a pivotal Phase III trial is expected to initiate in the US in 2006 for the same indication. A second product, acyclovir Lauriad ®, for the treatment of oral herpes, has recently completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the company’s doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the FDA.
This press release may not be transmitted and cannot constitute an offer of subscription or sale of shares in the countries where such an offer would violate applicable laws and regulations, including Australia, Canada, Japan and the United States of America. In particular, the shares of BioAlliance Pharma have not and will not be registered in the United States of America within the meaning of the Securities Act of 1933 as amended and will not be the subject of a public offering in the United States of America. Consequently, this press release may not be used for any offer or sale of shares in the United States of America unless such offer or sale is exempt from all applicable registration obligations. No communication relating to this public offering may be addressed to the United States of America or target the citizens of or persons residing or present in the United States of America.
For additional company background, click here.
Media and analysts contacts:
Piers Morgan
Chief Financial Officer
BioAlliance Pharma SA
Tel : +33 1 45 58 71 04
piers.morgan@bioalliancepharma.com
Andrew Lloyd & Associates
Andrew Lloyd, Gilles Pettitot
Tel : +33 1 56 54 07 00
allo@alla.com , gilles@alla.com
|
